News | May 04, 2026
Lilly posts explosive Q1 2026 results
Lifts full-year outlook as obesity drug boom accelerates
Lifts full-year outlook as obesity drug boom accelerates
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
But acquisition charges drag earnings into loss
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
The association is intended to strengthen healthcare delivery standards, particularly in Oncology services, and enhance patient care outcomes
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
